Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo

The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.

Study Overview

• Status: Completed
• Conditions: Anaemia
• Intervention / Treatment: Drug: Daprodustat (GSK1278863); Drug: Iron therapy; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 614
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Santa Fe, Argentina, 3000
    • GSK Investigational Site
  • Buenos Aires
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1128AAF
      • GSK Investigational Site
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425AGC
      • GSK Investigational Site
    • Mar del Plata, Buenos Aires, Argentina, B7600FZN
      • GSK Investigational Site
    • Mar del Plata, Buenos Aires, Argentina, 7600
      • GSK Investigational Site
    • San Nicolas, Buenos Aires, Argentina, B2900DMH
      • GSK Investigational Site
  • Córdova
    • Cordoba, Córdova, Argentina, 5003
      • GSK Investigational Site
  • Santa Fe
    • Rosario, Santa Fe, Argentina, S2000DEJ
      • GSK Investigational Site
• Australia
  • Fitzroy, Australia, 3065
    • GSK Investigational Site
  • New South Wales
    • Sydney, New South Wales, Australia, 2010
      • GSK Investigational Site
  • Victoria
    • Heidelberg, Victoria, Australia, 3084
      • GSK Investigational Site
    • Parkville, Victoria, Australia, 3050
      • GSK Investigational Site
  • Western Australia
    • Murdoch, Western Australia, Australia, 6150
      • GSK Investigational Site
• Brazil
  • São Paulo, Brazil, 04038002
    • GSK Investigational Site
  • Bahia
    • Feira de Santana., Bahia, Brazil, 44001-584
      • GSK Investigational Site
    • Salvador, Bahia, Brazil, 40415-065
      • GSK Investigational Site
  • Espírito Santo
    • Vitoria, Espírito Santo, Brazil, 29055450
      • GSK Investigational Site
  • São Paulo
    • Ribeirão Preto, São Paulo, Brazil, 14025170
      • GSK Investigational Site
    • Santo André - SP, São Paulo, Brazil, 09080-110
      • GSK Investigational Site
    • Sao Jose do Rio Preto, São Paulo, Brazil, 15090-000
      • GSK Investigational Site
    • Sao Jose do Rio Preto, São Paulo, Brazil, 15015200
      • GSK Investigational Site
    • São Bernardo do Campo, São Paulo, Brazil, 09715090
      • GSK Investigational Site
• Canada
  • Quebec, Canada, G3K 2P8
    • GSK Investigational Site
  • British Columbia
    • Victoria, British Columbia, Canada, V8V 4A1
      • GSK Investigational Site
  • Ontario
    • Brampton, Ontario, Canada, L6T 0G1
      • GSK Investigational Site
    • Guelph, Ontario, Canada, N1H 1B1
      • GSK Investigational Site
    • Kitchener, Ontario, Canada, N2H 5Z8
      • GSK Investigational Site
    • Ottawa, Ontario, Canada, K1H 1A2
      • GSK Investigational Site
    • Sarnia, Ontario, Canada, N7T 4X3
      • GSK Investigational Site
    • Sudbury, Ontario, Canada, P3A-1W8
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M5B 1W8
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M9V 4B4
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M9N 1N8
      • GSK Investigational Site
  • Quebec
    • Montréal, Quebec, Canada, H1M 1B1
      • GSK Investigational Site
    • Quebec city, Quebec, Canada, G2J 0C4
      • GSK Investigational Site
    • St-Charles-Borromée, Quebec, Canada, J6E 2B4
      • GSK Investigational Site
• France
  • Grenoble cedex 9, France, 38043
    • GSK Investigational Site
  • Le Mans cedex 9, France, 72037
    • GSK Investigational Site
  • Marseille cedex 5, France, 13385
    • GSK Investigational Site
  • Melun, France, 77000
    • GSK Investigational Site
  • Mulhouse cedex, France, 68070
    • GSK Investigational Site
  • Nantes Cedex 1, France, 44093
    • GSK Investigational Site
  • Nice Cedex 1, France, 06001
    • GSK Investigational Site
  • Saint-Priest en Jarez, France, 42270
    • GSK Investigational Site
• Italy
  • Calabria
    • Catanzaro, Calabria, Italy, 88100
      • GSK Investigational Site
  • Campania
    • Napoli, Campania, Italy, 80131
      • GSK Investigational Site
  • Emilia-Romagna
    • Bologna, Emilia-Romagna, Italy, 40138
      • GSK Investigational Site
    • Modena, Emilia-Romagna, Italy, 41124
      • GSK Investigational Site
  • Liguria
    • Genova, Liguria, Italy, 16132
      • GSK Investigational Site
  • Lombardia
    • Pavia, Lombardia, Italy, 27100
      • GSK Investigational Site
  • Veneto
    • Mestre, Veneto, Italy, 30174
      • GSK Investigational Site
• Korea, Republic of
  • Busan, Korea, Republic of, 49201
    • GSK Investigational Site
  • Busan, Korea, Republic of, 49241
    • GSK Investigational Site
  • Daegu, Korea, Republic of, 42415
    • GSK Investigational Site
  • Daegu-si, Korea, Republic of, 42601
    • GSK Investigational Site
  • Gyeonggi-do, Korea, Republic of, 463-712
    • GSK Investigational Site
  • Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
    • GSK Investigational Site
  • Seoul, Korea, Republic of, 08308
    • GSK Investigational Site
  • Seoul, Korea, Republic of, 03312
    • GSK Investigational Site
• Mexico
  • Guadalajara, Mexico, 44600
    • GSK Investigational Site
  • Merida, Mexico, 97000
    • GSK Investigational Site
  • Veracruz, Mexico, 91900
    • GSK Investigational Site
  • Guanajuato
    • Leon, Guanajuato, Mexico, 37530
      • GSK Investigational Site
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44150
      • GSK Investigational Site
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64060
      • GSK Investigational Site
  • Veracruz
    • Boca del Rio, Veracruz, Mexico, 24290
      • GSK Investigational Site
    • Córdoba, Veracruz, Mexico, 94550
      • GSK Investigational Site
  • Yucatán
    • Merida, Yucatán, Mexico, 97070
      • GSK Investigational Site
• Poland
  • Bialystok, Poland, 15-276
    • GSK Investigational Site
  • Ciechanow, Poland, 06-400
    • GSK Investigational Site
  • Krakow, Poland, 30510
    • GSK Investigational Site
  • Krakow, Poland, 31-513
    • GSK Investigational Site
  • Krakow, Poland, 31-559
    • GSK Investigational Site
  • Lodz, Poland, 92-213
    • GSK Investigational Site
  • Lublin, Poland, 20-064
    • GSK Investigational Site
  • Olawa, Poland, 55-200
    • GSK Investigational Site
  • Pleszew, Poland, 63-300
    • GSK Investigational Site
  • Sosnowiec, Poland, 41-200
    • GSK Investigational Site
  • Swidnik, Poland, 21-040
    • GSK Investigational Site
  • Szczecin, Poland, 70-111
    • GSK Investigational Site
  • Tczew, Poland, 83-110
    • GSK Investigational Site
  • Warszawa, Poland, 01-868
    • GSK Investigational Site
  • Warszawa, Poland, 02-801
    • GSK Investigational Site
  • Warszawa, Poland, 04-749
    • GSK Investigational Site
• Romania
  • Brasov, Romania, 500283
    • GSK Investigational Site
  • Bucharest, Romania, 022328
    • GSK Investigational Site
  • Bucharest, Romania, 042122
    • GSK Investigational Site
  • Cluj-Napoca, Romania, 400139
    • GSK Investigational Site
  • Craiova, Romania, 200642
    • GSK Investigational Site
  • Deva, Romania, 330084
    • GSK Investigational Site
  • Oradea, Romania, 410469
    • GSK Investigational Site
  • Targu Mures, Romania, 540096
    • GSK Investigational Site
  • Timisoara, Romania, 300723
    • GSK Investigational Site
• Russian Federation
  • Izhevsk, Russian Federation, 426061
    • GSK Investigational Site
  • Kaliningrad, Russian Federation, 236016
    • GSK Investigational Site
  • Kemerovo, Russian Federation, 650066
    • GSK Investigational Site
  • Krasnoyarsk, Russian Federation, 660022
    • GSK Investigational Site
  • Moscow, Russian Federation, 121359
    • GSK Investigational Site
  • Nizhniy Novgorod, Russian Federation, 603126
    • GSK Investigational Site
  • Pyatigorsk, Russian Federation, 357500
    • GSK Investigational Site
  • Pyatigorsk, Russian Federation, 357538
    • GSK Investigational Site
  • Rostov-on-Don, Russian Federation, 344022
    • GSK Investigational Site
  • Ryazan, Russian Federation, 390037
    • GSK Investigational Site
  • Saint Petersburg, Russian Federation, 197022
    • GSK Investigational Site
  • Saint Petersburg, Russian Federation, 194355
    • GSK Investigational Site
  • Stavropol, Russian Federation, 355017
    • GSK Investigational Site
  • Yaroslavl, Russian Federation, 150062
    • GSK Investigational Site
  • Yaroslavl, Russian Federation, 150000
    • GSK Investigational Site
  • Yaroslavl, Russian Federation, 150030
    • GSK Investigational Site
• Spain
  • Badalona, Spain, 08916
    • GSK Investigational Site
  • Madrid, Spain, 28040
    • GSK Investigational Site
  • Santiago de Compostela, Spain, 15890
    • GSK Investigational Site
• United Kingdom
  • Derby, United Kingdom, DE22 3NE
    • GSK Investigational Site
  • London, United Kingdom, SE5 9RS
    • GSK Investigational Site
  • Peterborough, United Kingdom, PE3 9GZ
    • GSK Investigational Site
  • Plymouth, United Kingdom, PL6 8DH
    • GSK Investigational Site
  • Shrewsbury, United Kingdom, SY3 8XQ
    • GSK Investigational Site
  • Swansea, United Kingdom, SA6 6NL
    • GSK Investigational Site
  • Kent
    • Canterbury, Kent, United Kingdom, CT1 3NG
      • GSK Investigational Site
• United States
  • Alabama
    • Homewood, Alabama, United States, 35209
      • GSK Investigational Site
  • Arkansas
    • Little Rock, Arkansas, United States, 72204
      • GSK Investigational Site
  • California
    • Downey, California, United States, 90242
      • GSK Investigational Site
    • Fresno, California, United States, 93720
      • GSK Investigational Site
    • Lynwood, California, United States, 90262
      • GSK Investigational Site
    • Northridge, California, United States, 91324
      • GSK Investigational Site
    • Northridge, California, United States, 91325
      • GSK Investigational Site
    • Riverside, California, United States, 82503
      • GSK Investigational Site
    • Salinas, California, United States, 93901
      • GSK Investigational Site
    • Santa Ana, California, United States, 92704
      • GSK Investigational Site
  • Colorado
    • Denver, Colorado, United States, 80230
      • GSK Investigational Site
  • Connecticut
    • Hartford, Connecticut, United States, 06112
      • GSK Investigational Site
    • Middlebury, Connecticut, United States, 06762
      • GSK Investigational Site
  • Florida
    • Coral Springs, Florida, United States, 33067
      • GSK Investigational Site
    • Hollywood, Florida, United States, 33024
      • GSK Investigational Site
    • Kissimmee, Florida, United States, 34741
      • GSK Investigational Site
    • Lauderdale Lakes, Florida, United States, 33313
      • GSK Investigational Site
    • Pembroke Pines, Florida, United States, 33028
      • GSK Investigational Site
    • Tampa, Florida, United States, 33614
      • GSK Investigational Site
  • Georgia
    • Adairsville, Georgia, United States, 30103
      • GSK Investigational Site
    • Macon, Georgia, United States, 31201
      • GSK Investigational Site
    • Macon, Georgia, United States, 31217
      • GSK Investigational Site
    • Statesboro, Georgia, United States, 30458
      • GSK Investigational Site
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • GSK Investigational Site
  • Kansas
    • Overland Park, Kansas, United States, 66210
      • GSK Investigational Site
  • Michigan
    • Buckley, Michigan, United States, 49620
      • GSK Investigational Site
    • Detroit, Michigan, United States, 48202
      • GSK Investigational Site
    • Saint Clair Shores, Michigan, United States, 48081
      • GSK Investigational Site
  • Mississippi
    • Brookhaven, Mississippi, United States, 39601
      • GSK Investigational Site
  • Missouri
    • Saint Louis, Missouri, United States, 63136
      • GSK Investigational Site
  • New Hampshire
    • Rochester, New Hampshire, United States, 03867
      • GSK Investigational Site
  • North Carolina
    • Asheville, North Carolina, United States, 28801
      • GSK Investigational Site
    • Charlotte, North Carolina, United States, 28262
      • GSK Investigational Site
    • Durham, North Carolina, United States, 27704
      • GSK Investigational Site
  • Oklahoma
    • Midwest City, Oklahoma, United States, 73130
      • GSK Investigational Site
    • Oklahoma City, Oklahoma, United States, 73112
      • GSK Investigational Site
  • Pennsylvania
    • Beaver, Pennsylvania, United States, 15009
      • GSK Investigational Site
    • Duncansville, Pennsylvania, United States, 16635
      • GSK Investigational Site
    • Scottdale, Pennsylvania, United States, 15683
      • GSK Investigational Site
    • Smithfield, Pennsylvania, United States, 15478
      • GSK Investigational Site
    • West Reading, Pennsylvania, United States, 19611
      • GSK Investigational Site
  • South Carolina
    • Orangeburg, South Carolina, United States, 29118
      • GSK Investigational Site
  • Tennessee
    • Kingsport, Tennessee, United States, 37660
      • GSK Investigational Site
    • Memphis, Tennessee, United States, 38163
      • GSK Investigational Site
  • Texas
    • DeSoto, Texas, United States, 75115
      • GSK Investigational Site
    • El Paso, Texas, United States, 79935
      • GSK Investigational Site
    • McAllen, Texas, United States, 78503
      • GSK Investigational Site
    • Waxahachie, Texas, United States, 75165
      • GSK Investigational Site
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• >=18 years of age at the time of signing the informed consent.
• Have CKD, confirmed at screening: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3, 4, or 5 defined by Estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) formula.
• Participants with Stable HemoCue Hgb from 8.5 to 10.5 at screening visit (Week -4) and from 8.5 to 10.0 g/dL at randomization (Day 1).
• Participants may receive up to one intravenous (IV) iron dose within the 8 weeks prior to screening and NO IV iron use between screening visit and randomization (Day 1).
• If needed, participant may be on stable maintenance oral iron supplementation. There should be <50% change in overall dose and no change in type of iron prescribed in the 4 weeks prior to Day 1 randomization visit.
• Male and female participants are eligible. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) or WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 4 weeks after the last dose of study treatment.
• Capable of giving signed informed consent.

Exclusion Criteria:

• Participants who are on dialysis or clinical evidence of impending need to initiate dialysis within 180 days after randomization (Day 1).
• Planned living-related or living-unrelated kidney transplant within 28 weeks after randomization (Day 1).
• Transferrin saturation (TSAT) <15 percent (Screening only).
• Ferritin <50 nanograms per milliliter (ng/mL) (Screening only).
• History of rhEPO or rhEPO analogue use within the 8 weeks prior to screening and rhEPO use between screening and randomization (Day 1).
• History of transfusion within the 8 weeks prior to screening and transfusion between screening and randomization (Day 1).
• History of bone marrow aplasia or pure red cell aplasia (PRCA).
• Participants with Megaloblastic anemia (untreated pernicious anemia and folate deficiency), thalassemia major, sickle cell disease or myelodysplastic syndrome.
• Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or clinically significant gastrointestinal (GI) bleeding <= 8 weeks prior to screening through to randomization (Day 1).
• History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product.
• Use of strong inhibitor of CYP2C8 (for example, gemfibrozil) or strong inducers of CYP2C8 (for example, rifampin/rifampicin).
• Ferric citrate use within 4 weeks prior to randomization (Day 1).
• Use of other investigational agent or device prior to screening through to randomization (Day 1).
• Any prior treatment with daprodustat for a treatment duration of >30 days.
• MI or acute coronary syndrome within the 8 weeks prior to screening through to randomization. (Day 1).
• Stroke or transient ischemic attack within the 8 weeks prior to screening through to randomization. (Day 1).
• Chronic Class IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.
• QT interval corrected by Bazett's formula (QTcB) >500 milliseconds (msec) or QTcB >530 msec in participants with bundle branch block. There is no corrected QT interval (QTc) exclusion for participants with a predominantly paced rhythm.
• Alanine transaminase (ALT) >2x upper limit of normal (ULN) at screening (Week -4).
• Bilirubin >1.5xULN at screening (Week -4).
• Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
• History of malignancy within the 2 years prior to screening through to randomization (Day 1), or currently receiving treatment for cancer, or complex kidney cyst (for example, Bosniak Category II F, III or IV) > 3 centimeters (cm).
• Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the participant at unacceptable risk, which may affect study compliance or prevent understanding of the aims or investigational procedures or possible consequences of the study.
• Current uncontrolled hypertension as determined by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Daprodustat receivers; Participants will receive oral daprodustat once daily	Drug: Daprodustat (GSK1278863); Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.; Drug: Iron therapy; Iron therapy will be administered if ferritin is <50 Nano gram per milliliter and/or TSAT is <15 percent.
Placebo Comparator: Placebo receivers; Participants will receive oral placebo once daily	Drug: Iron therapy; Iron therapy will be administered if ferritin is <50 Nano gram per milliliter and/or TSAT is <15 percent.; Drug: Placebo; Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28)	Blood samples were collected at given time points from participants for hemoglobin measurements. Evaluation period hemoglobin value was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 24 to Week 28 inclusive). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using the Analysis of Covariance (ANCOVA) model with terms for treatment, Baseline hemoglobin, and region.	Baseline (Day 1) and Week 24 to Week 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Hemoglobin Increase of >=1.0 Grams Per Deciliter From Baseline to Evaluation Period	Blood samples were collected at given time points for hemoglobin measurements. Evaluation period hemoglobin value was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 24 to Week 28 inclusive). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date. Percentage of participants with hemoglobin increase of >=1.0 grams per deciliter from Baseline to evaluation period was analyzed using Cochran-Mantel-Haenszel (CMH) chi-squared test. The percentage values presented has been rounded off.	Baseline (Day 1) and Week 24 to Week 28
Change From Baseline in Short Form-36 (SF-36) Questionnaire Vitality Domain Score by Traditional Scoring at Week 28	The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the 8 health domains: Physical Functioning, Role-Physical (role limitations caused by physical problems), Social Functioning, Bodily Pain, Mental Health, Role-Emotional (role limitations caused by emotional problems), Vitality, and General Perception of Health.Each domain is scored from 0 (poorer health) to 100 (better health). Vitality domain score ranges from 0-100; higher score indicates a better health state & better functioning. Change from Baseline was calculated as Post-Dose Visit Value at Week 28 minus Baseline. For primary analysis, the missing on-treatment Week 28 SF-36 Vitality domain scores were imputed using pre-specified multiple imputations. Baseline value was latest non-missing pre-dose assessment on or before randomization date. Analysis was performed using ANCOVA model with terms for treatment, Baseline score, and region.	Baseline (Day 1) and Week 28
Percentage of Participants With Hgb Response (Hgb in the 11-12 Grams/Deciliter Range) During Evaluation Period (Week 24 to Week 28 Inclusive)	Mean hemoglobin during the evaluation period was defined as the mean of all evaluable hemoglobin values during the evaluation period (Week 24 to Week 28 inclusive) including any evaluable unscheduled hemoglobin values that were taken during this period. Percentage of participants with Hgb response was defined as participants with mean Hgb within range (11-12 grams per deciliter during the evaluation period (Week 24 to Week 28 inclusive) and it was analyzed using Cochran-Mantel-Haenszel (CMH) chi-squared test. The percentage values presented has been rounded off.	Week 24 to Week 28
Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Hodges-Lehmann Estimate)	Percentage of days for which participant's Hgb was within the target range of 11-12 grams per deciliter during the evaluation period (Week 24 to Week 28 inclusive), including any unscheduled evaluable Hgb values that were taken during this time period. Percentage of time for which Hgb was within the target range (11-12 grams per deciliter) for a participant was calculated by dividing 'the total number of days that Hgb was within range during Week 24 to 28' by 'the total number of days the participant remained on treatment during Week 24 to 28'.	Week 24 to Week 28
Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Mann-Whitney Estimate)	Percentage of days for which participant's Hgb was within the target range of 11-12 grams per deciliter during the evaluation period (Week 24 to Week 28 inclusive), including any unscheduled evaluable Hgb values that were taken during this time period. Percentage of time for which Hgb was within the target range (11-12 grams per deciliter) for a participant was calculated by dividing 'the total number of days that Hgb was within range during Week 24 to 28' by 'the total number of days the participant remained on treatment during Week 24 to 28'	Week 24 to Week 28
Change From Baseline in Post-randomization Hgb at Week 28	Blood samples were collected at given time points for hemoglobin measurements. Change from Baseline in Hgb was analyzed using a mixed model repeated measures (MMRM) approach. Change from Baseline was calculated as Post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1) and Week 28
Rate of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria	The incidence rate of participants permanently stopping randomized treatment due to meeting rescue criteria is presented.	Up to Week 28
Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire	CKD-AQ is 21-item patient reported outcomes measure assessing symptoms & symptom impact in participants with anemia associated with CKD.CKD-AQ identified 3 domains:1.Tired/Low Energy/Weak scale consisting of ten items;2.Chest Pain/Shortness of Breath scale consisting of four items and 3.Cognitive scale consisting of three items;Single items included: 4.Difficulty Sleeping;5.Difficulty Standing for long periods of time;6.Severity-Shortness of breath while sitting/resting;7.Time with Shortness of breath while not doing activity.Single-item measures were recorded based on 0-100 scoring with 0 is worst possible & 100 is best possible score.Total domain score is calculated as average of items in each domain & ranged from 0-100 where 0 is worst possible and 100 is best possible score.Change from Baseline was calculated as post-dose visit value minus Baseline.Baseline was latest non-missing pre-dose assessment on or before randomization date. Adjusted mean & standard error is presented.	Baseline (Day 1) and Week 28
Change From Baseline in Patient Global Impression of Severity (PGI-S)	The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as Post-Dose visit value minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date. Adjusted mean and standard error is presented.	Baseline (Day 1) and Week 28
Change From Baseline in the SF-36 Physical Functioning Domain	The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following eight health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality, and general perception of health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning domain score ranges from 0-100; higher score indicates a better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1) and Week 28
Change From Baseline of the SF-36 Individual Items in the Vitality Domain	The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following eight health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality, and general perception of health. Individual vitality items include: 1. Did you feel full of life?, 2. Did you have a lot of energy?, 3. Did you feel worn out?, 4. Did you feel tired?. Score of each item in the vitality domain ranges from 0-100; higher score indicates better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1) and Week 28
Number of Participants Currently Employed as Per Work Productivity and Activity Impairment Questionnaire: Anemic Symptoms Clinical Practice Version (WPAI-ANS-CPV)	WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism(time missed from work), presenteeism(impairment at work) and regular daily activity impairment. WPAI questions (Q) were:1) currently employed,2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. WPAI generates 4 domain scores:percent (%) of work time missed(absenteeism),% of impairment while working(presenteeism),% of overall work impairment(absenteeism and presenteeism combined),% of activity impairment. Number of participants currently employed as per WPAI-ANS-CPV is presented.	Week 8, Week 12 and Week 28
Change From Baseline in WPAI-ANS-CPV: Percent Time Missed From Work	WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI questions (Q) were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4)overall work impairment due to problem, 5) activity impairment due to problem. Percent work time missed due to problem was a subscale and calculated as: Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1), Week 8, Week 12 and Week 28
Change From Baseline in WPAI-ANS-CPV: Mean Hours Missed From Work in the Past 7 Days	WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI Qs were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1), Week 8, Week 12 and Week 28
Change From Baseline in WPAI: Percent Impairment at Work	WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities.It contains 2 concepts-work productivity impairment measured via absenteeism(time missed from work),presenteeism(impairment at work) and regular daily activity impairment.WPAI Qs were:1)currently employed,2)work time missed due to problem,3)impairment while working due to problem,4)overall work impairment due to problem,5)activity impairment due to problem. % Impairment while Working due to Problem was subscale and calculated as: Q5/10 for those who were currently employed and actually worked in past 7 days. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before randomization date.	Baseline (Day 1), Week 8, Week 12 and Week 28
Change From Baseline in WPAI: Percent Overall Work Impairment	WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI Qs were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. Percent overall work impairment due to problem was a subscale and calculated as: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))×(Q5/10)] for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before randomization date.	Baseline (Day 1), Week 8, Week 12 and Week 28
Change From Baseline in WPAI: Percent Regular Daily Activity Impairment	WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities.It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI Qs were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. Percent activity impairment due to problem was a subscale and calculated as: Q5/10 for all respondents. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before randomization date.	Baseline (Day 1), Week 8, Week 12 and Week 28
Change From Baseline in EuroQol 5 Dimension 5 Level Health Utility Index (EQ-5D-5L) Utility Score	The EQ-5D-5L is a self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a 5-point Likert scale (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems). The responses for the five dimension together form a five-figure description of health state. Each of these five-figure health states have attached valuation (utility score), expressed as single index on a scale from 0-1, where 1 is full health and 0 is worst health. The higher the score the better the health status. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1) and Week 28
Change From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score	The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'the best health you can imagine' and 'the worst health you can imagine' at the time of completion. It is a self-assessment visual analogue scale, ranging from 0=worst imaginable to 100=best. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1) and Week 28
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP) at Week 28	SBP, DBP and MAP were measured with participants in a seated position after at least a 5-minute of rest. MAP is the average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date.	Baseline (Day 1) and Week 28
Percentage of Participants With at Least One Blood Pressure (BP) Exacerbation Event	Percentage of participants with at least one BP event is presented. BP exacerbation is defined as: SBP exacerbation: SBP >= 25 mmHg increase from Baseline or SBP >= 180 mmHg; DBP exacerbation: DBP >= 15 mmHg increase from Baseline or DBP >= 110 mmHg. Percentage of participants with at least one BP event is presented. The percentage values presented has been rounded off.	Up to Week 28

Collaborators and Investigators

• Sponsor: GlaxoSmithKline
• Investigators: Study Director: GSK Clinical Trials, GlaxoSmithKline

Publications and helpful links

General Publications

• Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
• Johansen KL, Cobitz AR, Singh AK, Macdougall IC, Lopes RD, Obrador GT, Kovesdy CP, Israni R, Jha V, Okoro T, Sprys M, Jolly S, Lindsay AC, Bhatt P, Camejo RR, Keeley T, Cizman B, Wheeler DC. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int. 2023 Jun;103(6):1180-1192. doi: 10.1016/j.kint.2023.02.019. Epub 2023 Mar 2.

Study record dates

Study Major Dates

• Study Start (Actual): March 5, 2018
• Primary Completion (Actual): October 7, 2020
• Study Completion (Actual): October 7, 2020

Study Registration Dates

• First Submitted: January 8, 2018
• First Submitted That Met QC Criteria: January 17, 2018
• First Posted (Actual): January 24, 2018

Study Record Updates

• Last Update Posted (Actual): April 2, 2024
• Last Update Submitted That Met QC Criteria: April 1, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Anemia; Chronic kidney disease; Hemoglobin; Daprodustat; Non-Dialysis; Recombinant human erythropoietin naïve
• Additional Relevant MeSH Terms: Pathologic Processes; Urologic Diseases; Disease Attributes; Hematologic Diseases; Renal Insufficiency; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Renal Insufficiency, Chronic; Anemia
• Other Study ID Numbers: 205270; 2017-002270-39 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
• IPD Sharing Time Frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
• IPD Sharing Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No